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Abstract
Chronic inflammation is an important risk factor for the development of colorectal cancer; however, themechanism of
tumorigenesis especially tumor progression to malignancy in the inflamed colon is still unclear. Our study shows that
epithelial signal transducer and activator of transcription 3 (STAT3), persistently activated in inflamed colon, is not re-
quired for inflammation-induced epithelial overproliferation and the development of early-stage tumors; however, it is
essential for tumor progression to advanced malignancy. We found that one of the mechanisms that epithelial STAT3
regulates in tumor progression might be to modify leukocytic infiltration in the large intestine. Activation of epithelial
STAT3 promotes the infiltration of the CD8+ lymphocyte population but inhibits the recruitment of regulatory T (Treg)
lymphocytes. The loss of Stat3 in epithelial cells promoted the expression of cytokines/chemokines including CCL19,
CCL28, and RANTES, which are known to be able to recruit Treg lymphocytes. Linked to these changes was the path-
way mediated by sphingosine 1-phosphate receptor 1 and sphingosine 1-phosphate kinases, which is activated in
colonic epithelial cells in inflamed colon with functional STAT3 but not in epithelial cells deleted of STAT3. Our data
suggest that epithelial STAT3 plays a critical role in inflammation-induced tumor progression through regulation of
leukocytic recruitment especially the infiltration of Treg cells in the large intestine.
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Introduction
Tumorigenesis is a multistage process often initiated by mutations
that activate oncogenes or inhibit tumor suppressor genes. However,
neoplastic cells often require additional factors from the microenvi-
ronment to support their survival, growth, and angiogenesis [1].
Clinical data and experimental mouse models have provided a defini-
tive link between inflammation and cancer [2,3]. Recent evidence has
shown that the activity of most of the inflammatory cytokines con-
verges on the nuclear factor κ-beta and signal transducer and activator
of transcription 3 (STAT3) [4,5]. However, the functions of STAT3
in tumor and stromal cells have not been clearly defined.
Transcriptional factor STAT3 is known to mediate inflammation
acting downstream of a number of cytokines including interleukin-6
(IL-6), IL-10, IL-17, IL-21, IL-23, and vascular endothelial growth
factor [4]. STAT3 functions in stromal cells have been shown to stim-
ulate CD8+ cell production of interferon-γ [6], stimulate regulatory
T (Treg) cells infiltrating into the tumor site [6], inhibit the matura-
tion of functional dendritic cells [7], and inhibit immune stimulation
in macrophages and neutrophils [8]. The anti-inflammatory effect of
IL-10 onmacrophage, for example, required STAT3 for its inhibition.
Thus, knockout of either IL-10 or Stat3 causes severe inflammation
[9,10]. Persistent activation of STAT3 has also been reported in many
solid tumors [5]. Depending on tumor type, STAT3 has diverse
functions. In head and neck tumors, for example, it has been shown
to regulate cell cycling in conjunctionwith cyclinD1 (or CCND1) [12],
and it inhibits cell growth by upregulating kinase inhibitor CDKN1B
(or p27Kip1) [13] in melanoma cells and inhibits apoptosis by sup-
pressing proapoptotic gene expression in breast, skin, and colon neo-
plastic cells [14–18]. Several reports have further shown that STAT3
activation in tumors is associated with poor prognosis [12,19–21],
suggesting that STAT3 promotes tumor progression and/or metastasis.
However, the mechanism by which STAT3 promotes tumor progres-
sion is unknown.
In the pathogenesis of inflammatory bowel disease and its associated
colorectal cancer, an aberrant signaling cascade involving IL-6, IL-10,
and STAT3 has been reported [3]. Recent genome-wide analysis of
Crohn disease has identified the Stat3 gene as one of the susceptibility
loci in this form of inflammatory bowel disease [22]. Furthermore,
somatic mutations of Stat3 linked to persistent activation of STAT3
and colorectal cancer have been shown [16]. A knock-in mouse model
in which constitutive active GP130 (gp130Y757F) leads to hyperactiva-
tion of JAK1/2-STAT3 signaling cascade on IL-6 binding develops
tumors during the inductive state of chronic inflammation [23].
Recently, a link between chronic inflammation and sphingosine
1-phosphate kinase 1 (SPHK1) in the development of colitis-associated
cancer was reported [24–26]. In all these models, the essential function
of STAT3/S1P in tumor growth was examined extensively, but the
role of STAT3 and its relationship with S1P in tumor progression has
not been addressed sufficiently.
We previously established a mouse model of spontaneous
inflammation-associated colonic cancer, conditional knockout mice
with Stat3 deletion in hematopoietic cells (Stat3-IKO), by inactivating
Stat3 in hematopoietic cells using colony-stimulating factor 1 receptor
promoter driving Cre recombinase in a control mouse with floxed
P sites in the introns of Stat3 gene (Stat3 flox/flox mouse) [10]. This
model has significant advantages for the study of this disease, because
a single myeloid mutation is used to generate chronic inflammation
that leads to tumor development at frequencies similar to human
colon cancer in the setting of inflammatory bowel disease (IBD)
[10]. Importantly, no germ line mutation is introduced into the
colonic epithelium, and consequently, the model is appropriate for
the study of early genetic and phenotypic changes within the critical
epithelial subsets. In this model, we found that STAT3 in epithelial
cells was persistently activated through early stage of inflammation
development, tumor formation, and tumor progression to malignancy.
To determine the role of STAT3 activation in epithelial/tumor cells in
inflamed colon, we have inactivated Stat3 specifically in the intestinal
epithelium of Stat3-IKO mice. In the Stat3 double knockout mice
[conditional knockout mice with Stat3 deletion in hematopoietic
and intestinal epithelial cells (Stat3-EIKO)], the colonic epithelium
still exhibited hyperproliferation and formation of early-stage tumors
in response to the chronic inflammation in the colons, but the rate
of tumorigenesis and progression to advanced malignancy was sig-
nificantly reduced. The delayed tumor progression is associated
with a decreased CD8+ cell and a reduced activation of sphingosine
1-phosphate receptor 1 (S1PR1)–SPHK1 pathway in epithelial cells
but an enhanced Treg lymphocyte in the large intestine, suggesting
that epithelial STAT3 regulates tumor progression by coordinating
immune cell recruitment using the S1PR1 pathway.
Materials and Methods
Mice and Human Samples
Mice were housed in the pathogen-free barrier facility at Albert
Einstein College of Medicine (AECOM, Bronx, NY) and were handled
in accordance with National Institutes of Health regulations concerning
the usage and care of experimental animals. All procedures involving
animal usage were approved by the Institutional Animal Care and
Use Committee (IACUC) committee at AECOM. Residual human
colonic tissues from biopsies or colectomy taken from patients with
inflammatory bowel disease and colorectal carcinoma, which would
otherwise be discarded, with Institutional Review Board (IRB)-
approved protocol 09-03-096X, were used. We have examined three
patient samples. One was a 71-year-old patient with a history of ulcera-
tive colitis (UC) and adenocarcinoma in a background of chronic active
colitis pathology. A second case was a 49-year-old male with UC for
7 years with low-grade dysplasia. A third case was a 66-year-old male
with UC and poorly differentiated carcinoma with signet ring mor-
phology and multifocal dysplasia. Negative samples were taken from
patients with diverticulitis or normal region of the colon from patients
with UC.
Stat3-IKO and Stat3-EIKO Mice
The establishment of Stat3-IKO mice was described previously
[10]. To delete Stat3 in intestinal epithelial cells in Stat3-IKO mice,
the transgene vCRE (Cre regulated by the villin promoter), kindly
provided by Dr Sylvie Robine (Institut Curie, Paris, France) [27],
was introduced into Stat3-IKO mice (in a C57BL/6 background) to
obtain mice with both hematopoietic and epithelial inactivation of
Stat3 (Stat3-EIKO mice).
Isolation of Colonic Epithelial Cells
Colonic epithelial cells were prepared as described previously [28].
Briefly, colons from the anal cavity to the cecum were removed from
the mice, cut into halves, and washed with Hank’s balanced salt solu-
tion (HBSS; Sigma, St Louis, MO) to remove fecal material. The
colons were treated with 1 mM DTT in HBSS for 10 minutes to
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remove the mucus. They were further treated with 25 ml of HBSS
with 1 mM EDTA at 37°C with shaking for 20 minutes, and colonic
epithelial cells were then scraped off the basal lamina. The scraped cells
were washed three times in HBSS and once in phosphate-buffered
saline (PBS) and then filtered through cell strainer with 70-μm nylon
mesh (BD Falcon; Fisher Scientific, Pittsburgh, PA). Epithelial cells were
isolated from 5 × 106 scraped cells using the biotinylated anti-mouse
CD326 epithelial cell adhesion molecule (CAM) antibody (Biolegend,
San Diego, CA) and CELLection Biotin Binder Kit (Invitrogen, Life
Technologies, Grand Island, NY) following the manufacturer’s protocol.
Quantitative Polymerase Chain Reaction
RNA from colonic epithelial cells was extracted using TRIzol
(Invitrogen). RNA (50-100 ng) was used in reverse transcription with
the Omniscript RT Kit (Qiagen, Valencia, CA). cDNA was subjected
to quantitative polymerase chain reaction (qPCR) using 0.1 μMprimers
from commercially available Mouse Cytokine Primer Library II (Real-
timePrimers.com) or from synthesized sequences (Sigma) and subjected
to 50 cycles of denaturation at 95°C for 10 seconds and annealing at
58°C for 45 seconds.
Histologic Analysis
The large intestine from mice were fixed in 10% formalin and
then paraffin embedded [28]. Sections were stained with hematoxylin
and eosin. The pathology of tissue sections were evaluated in blinded
fashion by Dr Qiang Liu, and disease stages were classified as follows:
Hyperplasia is characterized by thickened mucosa with elongated
crypts; low-grade dysplasia is classified by thickened mucosa with
elongated, irregularly branched glands that contain epithelium with
cytologic and nuclear atypia including loss of differentiation (goblet
cells), polarity, and enlarged nuclei; high-grade dysplasia has stratified
nuclei that are more extensive than low-grade dysplasia with loss of
cell polarity and presence of cribriform architecture or gland within
gland; carcinoma is characterized by tumor cell invasion into the
submucosa as the key distinguishing feature for this lesion. Specific
features also include the presence of atypical and irregular glands with
desmoplastic reaction.
Immunohistochemistry
Standard immunohistochemical (IHC) procedures were used
according to a protocol from Cell Signaling Technology (Danvers,
MA). All tissues stained for immune cells and intracellular molecules
were fixed with 10% formalin except for those stained for macrophages
with F4/80 antibody, which were fixed in zinc fixative (BD Biosciences,
San Jose, CA). Antibodies used were 0.1 μg/ml anti-F4/80 (Invitrogen),
3 μg/ml anti-CD3 (Dako Cytomation, Carpinteria, CA), 1:200 of
anti-MKI67 (or anti-Ki67), 4 μg/ml anti-pSTAT3 (Tyr705), 1:50 for
anti-pSTAT3 (Ser727), 1:400 for anti-BIRC5 (or anti-Survivin; Cell
Signaling Technology), 1:100 for anti–Forkhead box P3 (anti-FOXP3;
eBioscience, San Diego, CA), and 1:200 for anti–EDG-1 (S1PR1;
Abcam, Cambridge, MA).
Ex Vivo Organ Culture
Colons were isolated from mice, cut longitudinal, removed of fecal
material, and washed with HBSS. The colons were cut into 2- to
3-mmpieces and placed in serum-free RPMI media with antibiotic-
antimycotic (Gibco; Life Technologies, Grand Island, NY) before
incubation at 37°C. Supernatants from overnight culture were col-
lected, and chemokine and cytokine production were measured using
MILLIPLEX MAP Mouse Cytokine/Chemokine Panel Kit (EMD
Millipore, Billerica, MA) following the manufacturer’s protocol.
Flow Cytometry
Cells from scraped colons were washed in HBSS and passed
through a 70-μm filter. The cells were washed with FACS buffer
(0.5% BSA in PBS) and stained for the following surface proteins:
CD3+ T cells [CD3–fluorescein isothiocyanate (FITC)], CD4+ T cell
(CD4-FITC), CD8+ T cells [CD8-phycoerythrin (PE)], CD25+
T cells (CD25-PE) for 20 to 30 minutes. All fluorescent antibodies
were purchased from eBioscience and compared to recommended
isotype controls. The cells were washed once in FACS buffer and
then in PBS before fixation in 4% paraformaldehyde buffer for 20
to 30 minutes. Cells were washed three times in FACS buffer before
analysis using a Becton Dickinson FACScan Flow Cytometer.
Results
Inflammation-Induced Epithelial Overproliferation in Colon
Is Independent from STAT3
In a published study [10], we used the Stat3-IKOmodel to demon-
strate the role of mammalian target of rapamycin (mTOR), in putative
early stages of colitis-associated cancer, specifically the hyperprolifera-
tion of colonic epithelium and also the activation in these epithelial
cells of STAT3, which has been implicated in colon tumorigenesis by
other studies. To test the hypothesis that inflammation may promote
tumorigenesis through STAT3-mediated epithelial hyperproliferation,
we targeted inactivated Stat3 specifically in intestinal epithelial cells in
this model by crossing the transgene villin-Cre [27] into the Stat3-IKO
mice. The inactivation of epithelial Stat3 was efficient as shown by the
much lower density of the active form of STAT3 (pSTAT3) in colonic
epithelial cells in the double knockout mice, Stat3-EIKO (Figure 1A,
a and b vs c and d ), compared to the parental strain, Stat3-IKO.
No abnormality was observed in mice carrying villin-Cre and
Stat3 flox/flox [conditional knockout mice with Stat3 deletion in intes-
tinal epithelial cells (Stat3-VKO)], which are phenotypically similar
to Stat3 flox/flox control mice, suggesting that the activation of STAT3
in colonic epithelial cells in Stat3-IKO mice is specifically induced by
inflammation and it is not required for the normal development of
the large intestine. Unlike Stat3-IKO mice, which exhibited colitis
symptoms including persistent diarrhea, blood feces, and weight loss
by 18 to 20 weeks of age [10], age-matched littermates of Stat3-
EIKO mice appeared healthy and developed much milder symptoms
even in older mice (35-40 weeks of age). Examining the histology of
the large intestine, we found that, in a similar fashion to Stat3-IKO
mice, hyperproliferation of epithelial cells and an expanded prolifer-
ative compartment was observed in the large intestine of Stat3-EIKO
mice (Figure 1B, c and d vs a and b). There were many regions in
both Stat3-IKO and Stat3-EIKO colons with MKI67+ (or Ki67+)
cells extending up to 4/5 (80%) of the length of the crypt, whereas
most control (Stat3 flox/flox or Stat3-VKO) colons showed MKI67+ (or
Ki67+) cells only in the lower 1/2 (50%) of the crypt (Figure 1B, a
and b vs c and d ). A quantitative analysis of crypts with extended
MKI67+ (or Ki67+) epithelial cell proliferation demonstrated a sig-
nificant higher density of such crypts in the large intestines of both
Stat3-IKO and Stat3-EIKO mice compared to normal controls
(Figure 1C ) with no significant difference between Stat3-IKO and
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Stat3-EIKO colons, suggesting that epithelial cell overproliferation
can occur without functional epithelial Stat3. BIRC5 (or Survivin) is
a major downstream target of STAT3 and is known to have antiapop-
totic functions [11,29]. Analysis of BIRC5 (or Survivin) production
indicated that the functional BIRC5 (or Survivin) in Stat3-EIKO
colons was comparable to Stat3-IKO colons (Figure 1D). These data
support the idea that Survivin in colonic epithelial cells can be regulated
by intracellular signaling molecules other than STAT3 in inflamed
colon, as a deletion of intestinal Stat3 has little effect on the Stat3-EIKO
epithelial overproliferation.
Inactivation of Epithelial Stat3 Delayed Tumor Progression in
Inflamed Colon
There were significant differences in colonic histopathology between
age-matched Stat3-IKO and Stat3-EIKO littermates. Our previous
study classified tumor progression in the large intestine of Stat3-IKO
mice into three stages: low-grade dysplasia, high-grade dysplasia, and
carcinoma. Although both Stat3-IKO and Stat3-EIKOmice developed
hyperplasia in the large intestine at 14 weeks of age, most Stat3-IKO
mice exhibited high-grade dysplasia in colon by 24 weeks, while the
majority of age-matched Stat3-EIKO littermates had hyperplasia and a
few developed low-grade dysplasia in colon (Figure 2, A, c vs d, and Bi).
By 38 weeks of age, a large percentage of the Stat3-IKOmice had tumors
progressed to carcinoma with tumor invasion into the submucosa or
muscular layer, whereas none of the eight age-matched Stat3-EIKO
littermates exhibited progression to carcinoma (Figure 2A, e and g vs f ).
Further analysis of tumor stages revealed that a similar percentage of
both Stat3-IKO and Stat3-EIKO mice developed early-stage tumor,
low-grade dysplasia (Figure 2Bi, LD); a significant reduction of tumors
at advanced stages, including high-grade dysplasia and carcinoma, clas-
sifiedwith severe irregularly branched glands, cytologic andnuclear atypia,
as well as tumor invasion (Materials and Methods section), was observed
in Stat3-EIKO mice compared to Stat3-IKO mice (Figure 2Bi). Histo-
logic analysis also demonstrated a significant reduction of tumor inci-
dence observed in the Stat3-EIKO mice compared to Stat3-IKO mice
(Figure 2Bii). Neither inflammation nor tumors were found in control
Figure 1. Colonic hyperproliferation does not require functional STAT3. (A) IHC analysis of phosphorylated STAT3 (STAT3-P) in Stat3-IKO (a
and b) and Stat3-EIKO (c and d) colons. Boxed regions in a and c are shown at highermagnification in b and d. Red arrows in b and d point to
positive STAT3-P stromal cells, black arrow in b points to positive Stat3-IKO colonic epithelial cells, and black arrow in d points to cell loss of
STAT3-P. (B) IHC analysis for cellular proliferation. Representative sections show MKI67+ (or anti-Ki67+) cells extended up to 1/2 of the
crypt of control Stat3flox/flox (a) and Stat3-VKO (b) and to 4/5 of crypts of Stat3-IKO (c) and Stat3-EIKO (d) colons. (C) Significantly more
villi with MKI67+ extended up to 4/5 of the crypt are seen in both Stat3-IKO (c) and Stat3-EIKO (d) compared to control Stat3flox/flox (a) and
Stat3-VKO (b) [unpaired t test Stat3flox/flox vs Stat3-IKO or Stat3-EIKO. *P= .001 and **P= .0001 and no significant (ns) difference between
Stat3-IKO and Stat3-EIKO]. (D) IHC analysis shows that BIRC5 (or Survivin) is localized to the nucleus (black arrows) of epithelial cells
in Stat3-IKO and Stat3-EIKO colons taken from the same sections as in A (b and d).
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(Stat3flox/flox) or Stat3-VKO mice. Taken together, our data indicated
that activation of epithelial STAT3, induced by inflammation in
Stat3-IKO colon, is required for tumor progression to malignancy.
Epithelial STAT3 Regulates Leukocytic Infiltration in Colon
Our previous study has demonstrated a marked increase of macro-
phage infiltration, determined by macrophage-specific marker F4/80,
in the large intestine of Stat3-IKO mice compared to the normal con-
trols [10]. This was not reduced when epithelial Stat3 was inactivated
(Stat3-EIKO; Figure 3, A, a–c, and Bi). Similarly, a significant increase
of CD3+ lymphocytes was observed in Stat3-IKO colon compared to
normal control (Figure 3A, d vs e). In this case, however, inactivation
of epithelial Stat3 significantly reduced CD3+ T cell infiltration in the
colon of Stat3-EIKO compared to Stat3-IKO mice (Figure 3, A, e vs f,
and Bii). To further analyze T lymphocyte infiltration in the colon of
Stat3-EIKO mice, we examined the subpopulations of T lymphocytes
and found that inactivation of Stat3 in epithelial cells significantly
reduced the infiltration of CD8+ but not CD4+ lymphocytes in
the inflamed intestine of Stat3-EIKO compared to Stat3-IKO mice
(Figure 3, C and D). Consistent with the reduced infiltration of
CD8+ lymphocytes, a significant reduction of secretory proinflam-
matory cytokine IL-1α and a trend toward lower IL-6, tumor necrosis
factor-alpha (TNF-α), and IL-2 were found in colons of Stat3-EIKO
compared to Stat3-IKO mice, in which the production of these cyto-
kines was markedly increased relative to normal colon (Figure 4A).
These data suggest that inflammation-induced activation of STAT3
in colonic epithelial cells promote inflammation in colon by facilitating
proinflammatory cytokine expression.
To determine whether epithelial STAT3 regulated leukocytic in-
filtration in the colon, we next analyzed the expression of cytokines/
chemokines in isolated colonic epithelial cells using qPCR. Among
30 different chemokines in the CC and CXC families screened,
an increased production of IL-17 was observed in epithelial cells
from Stat3-IKO mice compared to normal controls, whereas inacti-
vation of Stat3 in the colonic epithelial cells reduced their expres-
sion (Figure 4B). In contrast, the expression of CCL19, CCL28,
and RANTES was mildly increased in epithelial cells isolated
from Stat3-IKO colon compared to normal control but highly
expressed in epithelial cells from Stat3-EIKO colon (Figure 4B),
indicating that this set of cytokines may be negatively regulated by
functional STAT3.
Because cytokines with higher expression in the colonic epithelial
cells of Stat3-EIKO compared to Stat3-IKO mice, including CCL19,
CCL28, and RANTES, were reported as Treg chemoattractants, we
next tested whether epithelial STAT3 regulates Treg cell recruitment
in the colon. FACS analysis of cells isolated from scraped colons and
gated for CD4+ and CD25+ population showed a reduced infiltration
of this population in Stat3-IKO colon compared to normal control
Figure 2. Loss of colonic epithelial Stat3 does not affect inflammation-induced hyperplasia. (A) Hematoxylin and eosin examination of
representative sections of large intestines at different ages. Early carcinoma is seen by 24 weeks of Stat3-IKO (c) and invasive carcinoma
by 38 weeks (e and higher magnification in g), whereas aged-matched Stat3-EIKO mice develop hyperplasia (d and f). Arrow in e points
to the invading front, and arrow in g points to dysplastic cells in the muscularis layer. (B) Graphical analysis of histologic differences
between Stat3-IKO and Stat3-EIKO colons taken from 14 to 38 weeks (n > 20). H, hyperplasia; LD, low-grade dysplasia; HD, high-grade
dysplasia; Car, carcinoma. (i) Significant difference is seen at the high-grade dysplasia stage and carcinoma between Stat3-IKO and
Stat3-EIKO large intestines [Fisher exact test (two-tail); *P < .05]. (ii) Significant difference is observed in the incidence of tumor devel-
opment in the Stat3-IKO compared to Stat3-EIKO mice (Fisher exact test, *P = .001).
1002 Epithelial STAT3 Tumor Progression Inflammation Nguyen et al. Neoplasia Vol. 15, No. 9, 2013
but a significant increase in the colons of Stat3-EIKO compared to
Stat3-IKO (Figure 4, C and D). Interestingly, a significantly higher
population of CD4+ CD25+ was also observed in Stat3-VKO colon
compared to Stat3-IKO or control colons. These observations sug-
gested that activation of epithelial STAT3 may have an inhibitory
effect on Treg infiltration in colon.We then verified the result by IHC
using an antibody that recognizes the Treg-specific marker, FOXP3
[30]. Although a three-fold increase of FOXP3+ T cells was found
in Stat3-IKO colon compared to the controls (Figure 4E , a vs b), an
additional two-fold increase of FOXP3+ T cells was observed in
Stat3-EIKO compared to Stat3-IKO colon (Figure 4E , b vs c; unpaired
t test, P = .0412). A totally eight-fold increase of FOXP3+ T cells was
found in the large intestine of Stat3-EIKO compared to Stat3-VKO
(unpaired t test, P < .0033). Taken together, consistent to the expres-
sion of pattern of cytokine/chemokine expression in colonic epithe-
lial cells in Stat3-IKO and Stat3-EIKO mice, the data suggest that
inflammation-induced activation of epithelial STAT3 plays a critical
role in regulating leukocytic infiltration in inflamed intestine and that
it promotes CD8+ but inhibits Treg infiltration in the large intestine.
Epithelial STAT3 Regulates Leukocytic Infiltration in
Colon Associated with S1P Pathway
In tumors with persistent activation of STAT3, the S1P signaling
pathway has been shown to act as a positive feedback loop that sup-
ports tumor cell growth involving IL-6 [31]. Because the ex vivo cul-
ture of both Stat3-IKO and Stat3-EIKO colons showed a robust IL-6
production (Figure 4A), we determined whether the S1P signaling
pathway was upregulated in these mice. IHC analysis for the S1PR1
receptor indicated that, in the inflamed areas of Stat3-IKO, there was
more intense staining of S1PR1 in colonic epithelial cells and stromal
cells compared to control colons (Stat3flox/flox or Stat3-VKO; Figure 5A,
a, b vs c). Fewer S1PR1+ cells were seen in the colon of Stat3-EIKO
mice compared to Stat3-IKO (Figure 5A, c vs d ). Interestingly, in
Stat3-IKO colon, S1PR1 appeared to be expressed on the cell surface
Figure 3. Epithelial STAT3 regulates inflammation. (A) IHC analysis of F4/80+macrophages (a–c) and CD3+T cells (d–f): control Stat3-VKO
(a and d), Stat3-IKO (b and e), and Stat3-EIKO (c and f). (B) Macrophage and CD3+ densities were quantified using National Institutes of
Health ImageJ: (i) A significant higher macrophage population is observed in either Stat3-IKO or Stat3-EIKO colons compared to control
(unpaired t test, *P= .0001) but no significant difference between Stat3-IKO and Stat3-EIKO. (ii) Significantly higher CD3+ T cell density is
observed in the Stat3-IKO compared to control or Stat3-EIKO (Stat3-IKO vs control, unpaired t test, * P= .02 and Stat3-IKO vs Stat3-EIKO,
unpaired t test, **P = .003). (C) FACS analysis of stromal cells in colons using CD4-FITC and CD8-PE. (D) Gated cells were used to
calculate the percentage of CD4+ and CD8+ T cells. CD4: Stat3-EIKO versus Stat3-VKO, unpaired t test, *P = .049; Stat3-IKO versus
Stat3-VKO, **P = .02. No significant difference in CD4+ T cell population between Stat3-IKO and Stat3-EIKO colons. CD8: Stat3-IKO
versus Stat3-VKO, unpaired t test, *P = .007 and Stat3-IKO versus Stat3-EIKO colons, **P = .0176.
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of the epithelial cells (Figure 5Ac, arrows), whereas in Stat3-EIKO colon,
S1PR1-positive staining appeared to be in enclosed vesicles in epithelial
cells (Figure 5Ad, arrow). The S1PR1 expression in isolated colonic
epithelial cells was verified by qPCR, which showed that Stat3-IKO ep-
ithelial cells had more than 10-fold higher expression than controls and
that inactivation of epithelial Stat3 significantly reduced the expression
(Figure 5Bi). Higher expression of S1PR1 suggested that this pathway
may be activated in the colonic epithelial cells in Stat3-IKO colon.
In a positive feedback loop, S1P, the substrate that binds S1PR1, is
phosphorylated by two kinases that are downstream targets of S1PR1
signaling [31,32]. Using qPCR analysis, we detected significantly in-
creased expression of SPHK2 in the epithelial cells of Stat3-IKO mice
compared to controls and Stat3-EIKO epithelial cells (Figure 5Bii). A
similar pattern was seen with SPHK1, but the expression did not show a
significant difference between Stat3-IKO and Stat3-EIKO. Consistent
with the observations in our mouse models, overexpression of S1PR1 in
the colonic epithelial cells of human IBD colon was verified by IHC. All
colon samples from three inflammatory bowel disease patients showed
intense S1PR1 staining in the colonic epithelium (Figure 5C ). Taken
together, these data indicate that the S1P pathway is active in human
inflammatory bowel disease and that the high expression of S1PR1 in
colonic epithelial cells in the inflamed sites is dependent on functional
epithelial STAT3 as a positive feedback mechanism.
Discussion
This study identified a novel role of epithelial STAT3 in inflammation-
induced tumor development in the large intestine. We demonstrated
that, in the large intestine with chronic inflammation, epithelial STAT3
is not required for inflammation-induced epithelial overproliferation
but is critical for tumor progression from early-stage malignancy
to invasive carcinoma. Because inactivation of Stat3 in epithelium
alone (Stat3-VKO) did not have any noticeable effect on colonic epithe-
lium, our study supports the hypothesis that the activation of epithelial
STAT3 in inflamed intestine is specifically linked to inflammation-
induced tumor development.
Our study highlights the function of epithelial STAT3 in tumor
development that is different from the commonly used models of
azoxymethane/dextran sodium sulfate (DSS)–induced colorectal cancers,
Figure 4. Colonic epithelial STAT3 regulates cytokine, chemokine production, and Treg recruitment. (A) Cytokine production (pg/ml) from
overnight organ culture. Stat3-IKO versus control Stat3-VKO, unpaired t test, *P= .0001 for IL-1α, *P= .02 for IL-6, *P= .0164 for TNF-α,
and *P= .0044 for IL-2. No significant (ns) difference in IL-6, TNF-α, and IL-2 production between Stat3-IKO and Stat3-EIKO culture, but a
significant difference is seen with IL-1α production, *P= .017. (B) Relative gene expression of chemokines from isolated colonic epithelial
cells. A higher trend of IL-17 expression is seen in Stat3-IKO compared to Stat3-EIKO and CCL19 in Stat3-EIKO compared to Sta3-IKO,
but a significant higher expression of CCL28 and RANTES is seen in Stat3-EIKO versus Stat3-IKO, unpaired t test, *P = .018 for CCL28
and **P = .04 for RANTES. (C) FACS analysis of CD4+ and CD25+ Treg cells. (D) A significantly higher population of CD4+CD25+ in
Stat3-EIKO colons and Stat3-VKO compared to Stat3-IKO colons, unpaired t test, *P = .048 and **P = .02. (E) IHC analysis of FOXP3+
cells in representative section from controls, Stat3-VKO (a; similar to Stat3flox/flox), Stat3-IKO (b), and Stat3-EIKO mice (c). Graphical analy-
sis of FOXP3+ cells/CD3+ T cells. Stat3-EIKO versus Stat3-IKO colons (unpaired t test, *P= .0412), Stat3-IKO versus Stat3-VKO (unpaired
t test, **P = .0149), and Stat3-EIKO versus Stat3-VKO (unpaired t test, ***P = .0033).
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in which epithelial STAT3 is believed to contribute to tumorigenesis in
inflamed colon by promoting tumor cell growth and inhibiting cell
death [23,33,34]. It is noteworthy that mice with functional epithelial
STAT3 under azoxymethane and DSS treatment developed tubular
adenomas as a consequence of compensatory hyperproliferation [23]
because of the physical damage of mucosal layer. Our model has sig-
nificant advantages for the study of tumorigenesis in chronic inflam-
mation such as inflammatory bowel diseases, because a single myeloid
mutation is used to generate chronic inflammation that leads to tumor
development at frequencies similar to human colon cancer in the setting
of IBD [10]. In contrast, in the DSS model, inflammation is second-
ary to acute mucosal injury that has overwhelming normal mucosal
immunity/functions.
Our data demonstrate a potential mechanistic link between epithelial
STAT3 and tumor progression. Activation of epithelial STAT3 in the
inflamed region is associated with overproduction of proinflammatory
cytokines in colon including IL-6, TNF-α, and IL-1α. Our data also
showed that an increased infiltration of CD8+ lymphocytes in colon
is linked to the activation of Stat3 in epithelial cells and tumor progres-
sion. The role of CD8+ lymphocytes in colitis-associated colorectal
cancer is still controversial in that CD8+ T cells is considered to play
a central role in cancer immunosurveillance, but these cells were also
found in intestinal mucosa of active IBD including both Crohn disease
and UC [35]. The infiltration of CD8+ T cells was reported to
have a direct cause of tissue damage and destruction of colonic epithelial
cells [36], which have the potential to favor tumor development. Our
data demonstrated that, consistent with the observation in human
IBD [35], an increased infiltration of CD8+ T cells is associated with
more severe inflammation and the development of advanced malig-
nancy in colon, whereas reduced tumor progression is correlated with
a decreased infiltration of CD8+ T cells, suggesting a protumorigenic
function of this population. We also demonstrated that the infiltration
of CD8+ is potentially regulated by epithelial STAT3.
Our data further suggest that inflammation-activated STAT3 in
epithelial cells may promote tumor progression through inhibiting
Treg recruitment in colon. Treg function primarily suppresses immune
responses by mediating tolerance against self-antigen or preventing ex-
cessive inflammation against intestinal microbes [37]. The role of Treg
in inflammation-associated cancer, however, is still unclear. Some
studies have shown that Treg cells suppress the anticancer immune
Figure 5. Persistent activation of epithelial STAT3 in inflammatory bowel diseases regulates the expression of S1PR1 receptor and
SPHKs. (A) Representative IHC analysis of S1PR1 receptor or EDG+ cells in Stat3 flox/flox (a), Stat3-VKO (b), Stat3-IKO (c), and Stat3-EIKO
colon (d). Red arrows point to S1PR1+ cells in stromal cells and in epithelial cells of Stat3-IKO and Stat3-EIKO colons (c and d).
(B) qPCR analysis of (i) S1PR1 and (ii) SPHK’s expression in the isolated colonic epithelial cells. Significantly higher expression of
S1PR1 is detected in Stat3-IKO colonic epithelial cells (Stat3-IKO vs control Stat3-VKO, unpaired t test, *P = .02 and Stat3-IKO vs
Stat3-EIKO, **P = .05), and significantly higher expression of SPHK2 is seen in Stat3-IKO colonic epithelial cells compared to control
and Stat3-EIKO (Stat3-IKO vs control Stat3-VKO, unpaired t test, *P = .028 and Stat3-IKO vs Stat3-EIKO, unpaired t test, **P = .039).
(C) Representative IHC section shows S1PR1-positive cells in biopsied colon taken from an inflammatory bowel disease patient (b) and
normal colon (a).
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reactions [38,39]; however, others have shown that Treg cells can repress
inflammation and therefore reduce inflammation-promoted tumor
risk [37]. Our finding that lower density of Treg cells is associated with
more advanced tumor progression, but intensive infiltration is associ-
ated with reduced tumor development, suggests the tumor inhibitory
role of Treg cells in colitis-associated colorectal cancer. This observa-
tion is supported by clinical studies that high density of FOXP3+ Treg
infiltration in colon cancer tissues was associated with improved survival
and more favorable prognosis [40,41]. Our study demonstrates a novel
regulation of Treg infiltration by epithelial STAT3 that may inhibit
the recruitment of this population through regulating the expression
of a set of cytokines and chemokines including CCL28, CCL19, and
RANTES. Several reports have shown that Treg expressed CCR4 and
CCR10 receptors for CCL22 and CCL28 [42,43] and, more re-
cently, CCR5 receptor for RANTES [44].
Activated STAT3 by inflammation in the colon may act as a key
component of a positive feedback cross talk between inflammatory
and epithelial cells. For example, IL-6, STAT3, and S1PR1 mediate
an autocrine loop that favors cancer cell growth [31,34,45]. In this
context, recruited stromal cells such as macrophages and T cells would
produce IL-6 that stimulates cancer cell growth by acting on the
STAT3 pathway. Our data would support this loop in tumor progres-
sion, as intense expression of S1PR1 is seen in areas with dysplastic cell
region of Stat3-IKO colons and moderate expression in hyperplastic
cell region of the Stat3-EIKO colons. Our observation that epithelial
cells with inflammation-activated STAT3 had higher expression of
SPHKs suggests further that STAT3 regulates the key enzymes respon-
sible for phosphorylation of sphingosine to S1P. Significantly high
CD4+ and CD8+ T cells seen in Stat3-IKO mice may be due to an
increase of S1P-regulating lymphocytes exiting from secondary lym-
phoid organs consistent with others showing S1PR1 and STAT3
induction in inflammatory responses [46]. Loss of epithelial Stat3 in
Stat3-EIKO showed that reduced expression of SPHK2 suggests epi-
thelial STAT3-mediating immune cell recruitment through S1P path-
way. Collectively, our data have established the linkage between
STAT3 regulation of SPHKs in the inflamed environment and tumor
progression. To our knowledge, this is the first time in which a link
between STAT3 and S1PR1 expression can be associated with a de-
fined stage of tumor progression (Figure 6).
In summary, we observed that epithelial STAT3 regulates tumor
progression but not the growth of the cells in the inflamed colon and
that epithelial STAT3 regulates leukocytic infiltration that may play
a crucial role in tumorigenesis and tumor progression. Epithelial
STAT3 may promote tumor progression through regulating the in-
filtration of proinflammatory cells and inhibiting Treg infiltration.
Recruited inflammatory cells may accelerate tumor progression
through the activation of the S1PR1 pathway in tumor cells. The
up-regulation of the S1P pathway is associated with advanced stage
of tumor progression, suggesting a possible target for therapeutic in-
tervention. A recent retrospective study of more than 900 patients
shows a significant association between colorectal cancer patients
with phosphatidylinositol 3-kinase mutation (PIK3CA) on regular
regimen of aspirin and reduced mortality rate [47]. This study dem-
onstrated the crucial role of inflammation, especially the interaction
between inflammation and tumor markers such a PI3K andMT-CO2
(or Cox2), in tumor progression in colorectal cancer. Our finding is
consistent with this study and further demonstrates that inflammation
regulated by epithelial STAT3 is critical for promoting tumor progres-
sion to advanced stage in colon. Interestingly, overexpression of
SPHK1 in cancer progression has been recently reviewed by Alshaker
et al. [48], and SPHK1 activation in cancer cells mediated by IL-6
through PI3K and mitogen-activated protein kinase (MAPK) path-
ways has also been reported [49]. Collectively, these data suggest that
SPHK1/S1P pathway regulates PI3K activity and inhibiting either
the upstream signaling cascade with S1P analog (dihydrosphingosine
or dimethylsphingosine), SPHK1 inhibitors (F-12509a, B-5354c, and
SKI-I-V) [48], or downstream through PI3K activity (aspirin) would
improve the clinical outcome of colorectal cancer. We are currently
evaluating the effectiveness of blocking the S1P signaling pathway with
immunosuppressive drug, such as fingolimod (FTY720) [50–52], in
our mouse model. The usage of FTY720 would offer additional strategy
that could be used to block inflammation-induced tumorigenesis.
Figure 6. Model of inflammatory bowel disease–associated colorectal cancer. During chronic inflammation, IL-6 activates epithelial
STAT3, which regulates S1P production through action of S1P/SPHK1 pathway. Recruited immune cells stimulated tumor progression
from hyperplasia to carcinoma.
1006 Epithelial STAT3 Tumor Progression Inflammation Nguyen et al. Neoplasia Vol. 15, No. 9, 2013
Acknowledgments
We thank Sylvie Robine (Institut Curie) for providing the villin-Cre
mice. We thank Ernestina Middleton, Joseph Albanese, Wa Shen,
Wai Ba, and Michele Houston for technical support and Neva
Morales-Grajales for administrative support. We thank the Pathology
Laboratory at Montefiore Medical Center and facilities at AECOM,
including Flow Cytometry, Analytical Imaging, Histology and Com-
parative Pathology, and Animal Housing, for the support.
References
[1] Joyce JA and Pollard JW (2009). Microenvironmental regulation of metastasis.
Nat Rev Cancer 9, 239–252.
[2] Mantovani A, Allavena P, Sica A, and Balkwill F (2008). Cancer-related inflam-
mation. Nature 454, 436–444.
[3] Karin M and Greten FR (2005). NF-κB: linking inflammation and immunity to
cancer development and progression. Nat Rev Immunol 5, 749–759.
[4] Yu H, Kortylewski M, and Pardoll D (2007). Crosstalk between cancer and
immune cells: role of STAT3 in the tumour microenvironment. Nat Rev
Immunol 7, 41–51.
[5] Yu H, Pardoll D, and Jove R (2009). STATs in cancer inflammation and
immunity: a leading role for STAT3. Nat Rev Cancer 9, 798–809.
[6] Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S,
Niu G, Kay H, Mulé J, Kerr WG, et al. (2005). Inhibiting Stat3 signaling in the
hematopoietic system elicits multicomponent antitumor immunity. Nat Med
11, 1314–1321.
[7] Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, Bhattacharya R,
Gabrilovich D, Heller R, Coppola D, et al. (2004). Regulation of the innate and
adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 10, 48–54.
[8] Takeda K, Clausen BE, Kaisho T, Tsujimura T, Terada N, Forster I, and Akira
S (1999). Enhanced Th1 activity and development of chronic enterocolitis in
mice devoid of Stat3 in macrophages and neutrophils. Immunity 10, 39–49.
[9] Rennick DM, Fort MM, and Davidson NJ (1997). Studies with IL-10−/− mice:
an overview. J Leukoc Biol 61, 389–396.
[10] Deng L, Zhou JF, Sellers RS, Li JF, Nguyen AV, Wang Y, Orlofsky A, Liu Q,
Hume DA, Pollard JW, et al. (2010). A novel mouse model of inflammatory
bowel disease links mammalian target of rapamycin-dependent hyperprolifera-
tion of colonic epithelium to inflammation-associated tumorigenesis. Am J
Pathol 176, 952–967.
[11] Ernst M and Putoczki TL (2012). Stat3: linking inflammation to (gastrointestinal)
tumourigenesis. Clin Exp Pharmacol Physiol 39, 711–718.
[12] Masuda M, Suzui M, Yasumatu R, Nakashima T, Kuratomi Y, Azuma K,
Tomita K, Komiyama S, and Weinstein IB (2002). Constitutive activation of
signal transducers and activators of transcription 3 correlates with cyclin D1 over-
expression and may provide a novel prognostic marker in head and neck squa-
mous cell carcinoma. Cancer Res 62, 3351–3355.
[13] Kortylewski M, Heinrich PC, Mackiewicz A, Schniertshauer U, Klingmuller U,
Nakajima K, Hirano T, Horn F, and Behrmann I (1999). Interleukin-6 and
oncostatin M-induced growth inhibition of human A375 melanoma cells is
STAT-dependent and involves upregulation of the cyclin-dependent kinase
inhibitor p27/Kip1. Oncogene 18, 3742–3753.
[14] Stephanou A, Brar BK, Knight RA, and Latchman DS (2000). Opposing actions
of STAT-1 and STAT-3 on the Bcl-2 and Bcl-x promoters. Cell Death Differ 7,
329–330.
[15] Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA, Cox CE,
Falcone R, Fairclough R, Parsons S, et al. (2001). Constitutive activation of
Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of
human breast carcinoma cells. Oncogene 20, 2499–2513.
[16] Corvinus FM, Orth C, Moriggl R, Tsareva SA, Wagner S, Pfitzner EB, Baus D,
Kaufmann R, Huber LA, Zatloukal K, et al. (2005). Persistent STAT3 activa-
tion in colon cancer is associated with enhanced cell proliferation and tumor
growth. Neoplasia 7, 545–555.
[17] Lin Q, Lai R, Chirieac LR, Li C, Thomazy VA, Grammatikakis I, Rassidakis
GZ, Zhang W, Fujio Y, Kunisada K, et al. (2005). Constitutive activation of
JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/
STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells.
Am J Pathol 167, 969–980.
[18] Timofeeva OA, Tarasova NI, Zhang X, Chasovskikh S, Cheema AK, Wang H,
Brown ML, and Dritschilo A (2013). STAT3 suppresses transcription of pro-
apoptotic genes in cancer cells with the involvement of its N-terminal domain.
Proc Natl Acad Sci USA 110, 1267–1272.
[19] Horiguchi A, Oya M, Shimada T, Uchida A, Marumo K, and Murai M (2002).
Activation of signal transducer and activator of transcription 3 in renal cell
carcinoma: a study of incidence and its association with pathological features
and clinical outcome. J Urol 168, 762–765.
[20] Kawada M, Seno H, Uenoyama Y, Sawabu T, Kanda N, Fukui H, Shimahara Y,
andChiba T (2006). Signal transducers and activators of transcription 3 activation
is involved in nuclear accumulation of β-catenin in colorectal cancer. Cancer
Res 66, 2913–2917.
[21] Morikawa T, Baba Y, Yamauchi M, Kuchiba A, Nosho K, Shima K, Tanaka N,
Huttenhower C, Frank DA, Fuchs CS, et al. (2011). STAT3 expression, molec-
ular features, inflammation patterns, and prognosis in a database of 724 colorectal
cancers. Clin Cancer Res 17, 1452–1462.
[22] Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, Brant SR,
Silverberg MS, Taylor KD, Barmada MM, et al. (2008). Genome-wide associ-
ation defines more than 30 distinct susceptibility loci for Crohn’s disease. Nat
Genet 40, 955–962.
[23] Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, Bennecke M, Bateman T,
Nebelsiek T, Lundgren-May T, Canli O, Schwitalla S, et al. (2009). gp130-
mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle
progression during colitis-associated tumorigenesis. Cancer Cell 15, 91–102.
[24] Kawamori T, Kaneshiro T, Okumura M, Maalouf S, Uflacker A, Bielawski J,
Hannun YA, and Obeid LM (2009). Role for sphingosine kinase 1 in colon
carcinogenesis. FASEB J 23, 405–414.
[25] Snider AJ, Kawamori T, Bradshaw SG, Orr KA, Gilkeson GS, Hannun YA, and
Obeid LM (2009). A role for sphingosine kinase 1 in dextran sulfate sodium-
induced colitis. FASEB J 23, 143–152.
[26] Liang J, Nagahashi M, Kim EY, Harikumar KB, Yamada A, Huang WC, Hait
NC, Allegood JC, Price MM, Avni D, et al. (2013). Sphingosine-1-phosphate
links persistent STAT3 activation, chronic intestinal inflammation, and devel-
opment of colitis-associated cancer. Cancer Cell 23, 107–120.
[27] el Marjou F, Janssen KP, Chang BH, Li M, Hindie V, Chan L, Louvard D,
Chambon P, Metzger D, and Robine S (2004). Tissue-specific and inducible
Cre-mediated recombination in the gut epithelium. Genesis 39, 186–193.
[28] Rigas B, Tsioulias GJ, Allan C, Wali RK, and Brasitus TA (1994). The effect of
bile acids and piroxicam on MHC antigen expression in rat colonocytes during
colon cancer development. Immunology 83, 319–323.
[29] Diaz N, Minton S, Cox C, Bowman T, Gritsko T, Garcia R, Eweis I, Wloch M,
Livingston S, Seijo E, et al. (2006). Activation of Stat3 in primary tumors from
high-risk breast cancer patients is associated with elevated levels of activated
SRC and survivin expression. Clin Cancer Res 12, 20–28.
[30] Hori S, Nomura T, and Sakaguchi S (2003). Control of regulatory T cell devel-
opment by the transcription factor Foxp3. Science 299, 1057–1061.
[31] Lee H, Deng J, Kujawski M, Yang C, Liu Y, Herrmann A, Kortylewski M,
Horne D, Somlo G, Forman S, et al. (2010). STAT3-induced S1PR1 expression
is crucial for persistent STAT3 activation in tumors. Nat Med 16, 1421–1428.
[32] Olivera A, Kohama T, Tu Z, Milstien S, and Spiegel S (1998). Purification
and characterization of rat kidney sphingosine kinase. J Biol Chem 273,
12576–12583.
[33] Waldner MJ, Wirtz S, Jefremow A, Warntjen M, Neufert C, Atreya R, Becker C,
Weigmann B, Vieth M, Rose-John S, et al. (2010). VEGF receptor signaling
links inflammation and tumorigenesis in colitis-associated cancer. J Exp Med
207, 2855–2868.
[34] Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S,
Scheller J, Rose-John S, Cheroutre H, Eckmann L, et al. (2009). IL-6 and
Stat3 are required for survival of intestinal epithelial cells and development of
colitis-associated cancer. Cancer Cell 15, 103–113.
[35] Muller S, Lory J, Corazza N, Griffiths GM, Z’Graggen K, Mazzucchelli L,
Kappeler A, and Mueller C (1998). Activated CD4+ and CD8+ cytotoxic cells
are present in increased numbers in the intestinal mucosa from patients with
active inflammatory bowel disease. Am J Pathol 152, 261–268.
[36] Okazaki K, Morita M, Nishimori I, Sano S, Toyonaga M, Nakazawa Y, and
Yamamoto Y (1993). Major histocompatibility antigen-restricted cytotoxicity
in inflammatory bowel disease. Gastroenterology 104, 384–391.
[37] Erdman SE, Rao VP, Olipitz W, Taylor CL, Jackson EA, Levkovich T, Lee
CW, Horwitz BH, Fox JG, Ge Z, et al. (2010). Unifying roles for regulatory
T cells and inflammation in cancer. Int J Cancer 126, 1651–1665.
[38] Atreya I and Neurath MF (2008). Immune cells in colorectal cancer: prognostic
relevance and therapeutic strategies. Expert Rev Anticancer Ther 8, 561–572.
Neoplasia Vol. 15, No. 9, 2013 Epithelial STAT3 Tumor Progression Inflammation Nguyen et al. 1007
[39] Deschoolmeester V, Baay M, Lardon F, Pauwels P, and Peeters M (2011).
Immune cells in colorectal cancer: prognostic relevance and role of MSI. Cancer
Microenviron 4, 377–392.
[40] Ladoire S, Martin F, and Ghiringhelli F (2011). Prognostic role of FOXP3+
regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer.
Cancer Immunol Immunother 60, 909–918.
[41] Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D, Platell C, and
Iacopetta B (2009). Tumor-infiltrating FOXP3+ T regulatory cells show strong
prognostic significance in colorectal cancer. J Clin Oncol 27, 186–192.
[42] Eksteen B, Miles A, Curbishley SM, Tselepis C, Grant AJ, Walker LS, and
Adams DH (2006). Epithelial inflammation is associated with CCL28 produc-
tion and the recruitment of regulatory T cells expressing CCR10. J Immunol
177, 593–603.
[43] Iellem A, Mariani M, Lang R, Recalde H, Panina-Bordignon P, Sinigaglia F,
and D’Ambrosio D (2001). Unique chemotactic response profile and specific
expression of chemokine receptors CCR4 and CCR8 by CD4+CD25+ regulatory
T cells. J Exp Med 194, 847–853.
[44] Tan MC, Goedegebuure PS, Belt BA, Flaherty B, Sankpal N, Gillanders WE,
Eberlein TJ, Hsieh CS, and LinehanDC (2009). Disruption of CCR5-dependent
homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic
cancer. J Immunol 182, 1746–1755.
[45] Grivennikov S and Karin M (2008). Autocrine IL-6 signaling: a key event in
tumorigenesis? Cancer Cell 13, 7–9.
[46] Gurgui M, Broere R, Kalff JC, and van Echten-Deckert G (2010). Dual action
of sphingosine 1-phosphate in eliciting proinflammatory responses in primary
cultured rat intestinal smooth muscle cells. Cell Signal 22, 1727–1733.
[47] Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M,
Imamura Y, Qian ZR, Baba Y, Shima K, et al. (2012). Aspirin use, tumor PIK3-
CA mutation, and colorectal-cancer survival. N Engl J Med 367, 1596–1606.
[48] Alshaker H, Sauer L, Monteil D, Ottaviani S, Srivats S, Bohler T, and
Pchejetski D (2013). Therapeutic potential of targeting SK1 in human cancers.
Adv Cancer Res 117, 143–200.
[49] Pchejetski D, Nunes J, Coughlan K, Lall H, Pitson SM, Waxman J, and
Sumbayev VV (2011). The involvement of sphingosine kinase 1 in LPS-induced
Toll-like receptor 4-mediated accumulation of HIF-1α protein, activation of
ASK1 and production of the pro-inflammatory cytokine IL-6. Immunol Cell
Biol 89, 268–274.
[50] Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, Allende
ML, Proia RL, and Cyster JG (2004). Lymphocyte egress from thymus and periph-
eral lymphoid organs is dependent on S1P receptor 1. Nature 427, 355–360.
[51] Azuma H, Takahara S, Ichimaru N, Wang JD, Itoh Y, Otsuki Y, Morimoto J,
Fukui R, Hoshiga M, Ishihara T, et al. (2002). Marked prevention of tumor
growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse
breast cancer models. Cancer Res 62, 1410–1419.
[52] Daniel C, Sartory N, Zahn N, Geisslinger G, Radeke HH, and Stein JM
(2007). FTY720 ameliorates Th1-mediated colitis in mice by directly affecting
the functional activity of CD4+CD25+ regulatory T cells. J Immunol 178,
2458–2468.
1008 Epithelial STAT3 Tumor Progression Inflammation Nguyen et al. Neoplasia Vol. 15, No. 9, 2013
